Zymeworks EPS - Earnings per Share 2016-2022 | ZYME
Zymeworks eps - earnings per share from 2016 to 2022. Eps - earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
| Zymeworks Annual EPS |
| 2021 |
$-4.61 |
| 2020 |
$-3.58 |
| 2019 |
$-3.83 |
| 2018 |
$-1.26 |
| 2017 |
$-0.64 |
| 2016 |
$-2.65 |
| 2015 |
$-0.71 |
| Zymeworks Quarterly EPS |
| 2022-06-30 |
$-0.97 |
| 2022-03-31 |
$-1.19 |
| 2021-12-31 |
$-1.18 |
| 2021-09-30 |
$-1.25 |
| 2021-06-30 |
$-1.31 |
| 2021-03-31 |
$-0.87 |
| 2020-12-31 |
$-0.74 |
| 2020-09-30 |
$-1.43 |
| 2020-06-30 |
$-0.77 |
| 2020-03-31 |
$-0.64 |
| 2019-12-31 |
$-1.81 |
| 2019-09-30 |
$-0.70 |
| 2019-06-30 |
$-0.89 |
| 2019-03-31 |
$-0.43 |
| 2018-12-31 |
$0.38 |
| 2018-09-30 |
$-0.59 |
| 2018-06-30 |
$-0.22 |
| 2018-03-31 |
$-0.83 |
| 2017-12-31 |
$1.89 |
| 2017-09-30 |
$-0.65 |
| 2017-06-30 |
$-0.63 |
| 2017-03-31 |
$-1.25 |
| 2016-12-31 |
$-0.89 |
| 2016-09-30 |
$-0.94 |
| 2016-06-30 |
$-0.58 |
| 2016-03-31 |
$-0.24 |
| 2015-12-31 |
$0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.553B |
$0.412B |
|
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
|
